durvalumab + pomalidomide + dexamethasone

This is a **combination therapy** consisting of durvalumab (a monoclonal antibody targeting programmed death-ligand 1 (PD-L1)), pomalidomide (an immunomodulatory drug), and dexamethasone (a synthetic glucocorticoid corticosteroid) used experimentally for the treatment of relapsed/refractory multiple myeloma. **Durvalumab** blocks PD-L1 to restore immune response against tumor cells, **pomalidomide** modulates the immune microenvironment and promotes direct tumoricidal effects, and **dexamethasone** provides anti-inflammatory and immunosuppressive effects that support treatment tolerance[1][5]. The combination results in increased activation of peripheral immune cells, significant gene expression changes in the tumor microenvironment, and an enhanced immunomodulatory effect compared to durvalumab monotherapy[1][5]. This regimen has been primarily assessed in phase 1b clinical trials for relapsed/refractory multiple myeloma, with development halted due to safety concerns regarding immune checkpoint inhibitor combinations in this disease[3][5].

Other names

durvalumab + pomalidomide + dexamethasone